Synonyms: DAR 0100A | DAR-0100A | DAR0100A
Compound class:
Synthetic organic
Comment: Dihydrexidine is a moderately selective full agonist at the dopamine D1 and D5 receptors. Currently undergoing clinical trials to assess its efficacy in improving the cognitive and working memory deficits in schizophrenia and schizotypal disorder. Results of a proof-of-principle study are reported in [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
See Phase 2 trial NCT02507206. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02507206 | A D1 Agonist For Working Memory | Phase 2 Interventional | Icahn School of Medicine at Mount Sinai |